10月20日，Tempus AI盘中上涨5.1%，报67.66美元／股，成交额8359.79万美元。
消息面上，公司此前宣布扩大与Moderna及Merck的多年合作，以支持个体化癌症疗法intismeran autogene的潜在商业化，市场继续围绕其肿瘤精准医疗与测序服务能力进行交易。
根据披露，Tempus将负责肿瘤组织及血液样本采集、转运和测序，并提供下一代测序服务，以支持疗法设计和生产。结合公司近期持续推进多模态基因组数据平台与AI医疗产品布局，该合作进一步强化其在精准医疗基础设施中的角色。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.